Site search
2811 results for '' found
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in P
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in P
/
A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)
A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)
/
(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)
(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)
/
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)
/
The Intelligent Computerized Engine (ICE) Aspiration System Clinical Study: First In Human
The Intelligent Computerized Engine (ICE) Aspiration System Clinical Study: First In Human
/
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (ACTRN1262100103789
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (ACTRN1262100103789
/
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients with Metastatic Castration-Resistant Prostate Cancer HP518-CS-001 (NCT05252364
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients with Metastatic Castration-Resistant Prostate Cancer HP518-CS-001 (NCT05252364
/
HOME-AKI: Haemofiltration with Oxiris: Multicentre Evaluation in Acute Kidney Injury (U1111-1247-3435)
HOME-AKI: Haemofiltration with Oxiris: Multicentre Evaluation in Acute Kidney Injury (U1111-1247-3435)
/
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with
/
Home-based Minimal Equipment Exercise Training (H-MEET) delivered using remote supervision: A randomised controlled feasibility study (ACTRN12625000550404)
Home-based Minimal Equipment Exercise Training (H-MEET) delivered using remote supervision: A randomised controlled feasibility study (ACTRN12625000550404)
/